The nation of Zimbabwe has rejected a major American health deal worth $367m (272 million pounds) over five years because of the United States' demand for confidential data.
This move was revealed after a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "lopsided".
An official spokesman has since explained that the United States was seeking genetic material for research and commercial purposes but was not willing to share the benefits from future treatments.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for more negotiations to secure a deal suitable to both sides so the nation's critical HIV treatment initiative can continue.
Wider Implications
Zimbabwe's decision comes after a comparable situation in Kenya, where a court blocked a similar health funding agreement after legal challenges were filed about the safety of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and responsibility.
As per statements, 16 African countries have to date signed these new health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Agreement
This assistance for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that might result from that provided information," he stated.
"Put simply, our country would provide the raw materials for scientific discovery with no certainty that the final treatments would be available to our citizens if a future health crisis arise."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one health agreements were undermining structures already set up through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This framework is intended to ensure that when a country contributes its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent collaboration might be designed in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts expressed it acknowledged the official position, but urged that talks should continue given that a large portion of the nation's Aids initiatives relied on foreign aid.
"Where specific concerns exist, such as those involving information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," the group commented.
The situation highlights the ongoing challenges between receiving much-needed international aid and safeguarding a country's data in an increasingly data-driven world.